Fredun Pharmaceuticals Limited has successfully completed its preferential allotment of equity shares and warrants, raising ₹97.49 crores from 62 investors. The Board of Directors approved the allotment on December 29, 2025, following member approval from the Extra-Ordinary General Meeting held on October 22, 2025, and in-principle approval from BSE Limited dated December 19, 2025.

Allotment Details and Structure

The company has allotted securities at ₹1,250.00 per share, including a premium of ₹1,240.00, representing a significant capital raise for its expansion plans:

The convertible warrants carry the right to subscribe to one equity share each and are exercisable within 18 months from the allotment date. The company received ₹17.24 crores as warrant subscription price, representing 25% of the total warrant value.

Investor Distribution and Participation

The allotment includes participation from both promoter and non-promoter categories across 62 investors:

Major Institutional Investors

Significant institutional participation includes prominent investment firms and funds:

Promoter Participation

Promoter participation strengthens management commitment to the company's growth trajectory:

Post-Allotment Shareholding Impact

The preferential allotment will result in changes to the company's shareholding structure. Based on the allotment data, the company's paid-up equity share capital is expected to increase significantly, with the new investor base bringing diverse institutional and individual participation.

Strategic Fund Utilization Framework

The raised capital will support Fredun Pharmaceuticals' multi-pronged expansion strategy across integrated health, wellness, and pharmaceutical sectors. The company plans to deploy funds across brand marketing and distribution (35%), working capital requirements (35%), strategic reserves (15%), formulation development and R&D (5%), CAPEX (5%), and contingency provisions (5%).

Business Expansion Initiatives

Fredun Pharmaceuticals is pursuing strategic expansion into three key divisions:

Pet Care Division: Focusing on functional nutrition, dermatology, and therapeutic wellness for companion animals with specialized product lines.

Human Care Division: Addressing lifestyle-driven health challenges through nutritional, cosmeceutical, and dermatological solutions.

Pharma Generics Division: Entry into regulated pharmaceutical markets with cost-effective, high-quality generic formulations targeting nine international markets including Sri Lanka, Philippines, Nigeria, UAE, and Mali.

Regulatory Compliance and Lock-in Provisions

All securities allotted under the preferential issue are subject to lock-in restrictions as prescribed under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. The allotment process adhered to all regulatory requirements under SEBI LODR Regulations and received necessary approvals from BSE Limited.

The successful completion of this preferential allotment positions Fredun Pharmaceuticals to execute its comprehensive expansion strategy across multiple healthcare segments while strengthening its financial foundation for sustained growth.

Fredun Pharmaceuticals Limited , a prominent player in the pharmaceutical sector, has announced a significant change in its corporate structure. Parag Goyal, who has been serving as the Company Secretary and Compliance Officer, is set to resign from his position.

Key Details of the Resignation

• Effective Date: Parag Goyal's resignation will take effect from the close of working hours on November 26, 2025.
• Reason: The resignation has been attributed to personal commitments.
• Acceptance: The Board of Directors has accepted Goyal's resignation.

Company's Response

Fredun Pharmaceuticals has stated that it will inform the stock exchanges once a new Company Secretary and Compliance Officer is appointed. This move ensures transparency and compliance with regulatory requirements.

Acknowledgment

In his resignation letter, Parag Goyal expressed gratitude for the opportunity to serve Fredun Pharmaceuticals Limited. He acknowledged the trust, support, and cooperation extended to him by all members of the Board during his tenure.

Regulatory Compliance

The company has duly informed the BSE Ltd. about this development, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Fredun Pharmaceuticals has also provided the necessary details as required under these regulations.

Financial Performance Context

While this corporate change is taking place, it's worth noting that Fredun Pharmaceuticals has recently reported its financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these unaudited financial results in a meeting held on November 8, 2025.

This corporate governance update comes at a time when the company has shown strong financial performance, with a significant increase in net sales and profitability compared to the previous year.

As Fredun Pharmaceuticals navigates this transition in its key compliance role, stakeholders will be watching for the appointment of a new Company Secretary and Compliance Officer to ensure continued adherence to regulatory standards and smooth corporate operations.